Integrated approach of in vivo and in vitro evaluation of the involvement of hepatic uptake organic anion transporters in the drug disposition in rats using rifampicin as an inhibitor

Drug Metabolism and Disposition

Volumn 41, Issue 7, 2013, Pages 1442-1449

  Imaoka, Tomoki ^a   Mikkaichi, Tsuyoshi ^a   Abe, Koji ^a   Hirouchi, Masakazu ^a   Okudaira, Noriko ^a   Izumi, Takashi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BROMSULFOPHTHALEIN; CERIVASTATIN; CYTOCHROME P450 3A; FLUINDOSTATIN; MIDAZOLAM; ORGANIC ANION TRANSPORTER; PITAVASTATIN; PRAVASTATIN; RIFAMPICIN; ROSUVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG RESEARCH; DRUG UPTAKE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; DRUG INTERACTIONS; FEMALE; HEPATOCYTES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; METABOLIC CLEARANCE RATE; MIDAZOLAM; ORGANIC ANION TRANSPORTERS; RATS; RATS, SPRAGUE-DAWLEY; RIFAMPIN; SULFOBROMOPHTHALEIN;

RATTUS;

EID: 84879093425     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.051052     Document Type: Article

References (21)

1. Boberg M, Angerbauer R, Kanhai WK, Karl W, Kern A, Radtke M, and Steinke W (1998) Biotransformation of cerivastatin in mice, rats, and dogs in vivo. Drug Metab Dispos 26:640-652.
2. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
3. Fardel O, Lecureur V, Loyer P, and Guillouzo A (1995) Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells. Biochem Pharmacol 49:1255-1260.
4. Fujiyama N, Shitara Y, Ito K, Masubuchi Y, and Horie T (2007) Down-regulation of hepatic transporters for BSP in rats with indomethacin-induced intestinal injury. Biol Pharm Bull 30:556-561.
5. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
6. Gardiner P and Paine SW (2011) The impact of hepatic uptake on the pharmacokinetics of organic anions. Drug Metab Dispos 39:1930-1938.
7. Institute of Laboratory Animal Resources; National Research Council (NRC) (1996). Guide for the Care and Use of Laboratory Animals, National Academy Press, Washington, DC.
8. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171.
9. Kajosaari LI, Laitila J, Neuvonen PJ, and Backman JT (2005) Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 97:249-256.
10. Kalgutkar AS, Feng B, Nguyen HT, Frederick KS, Campbell SD, Hatch HL, Bi YA, Kazolias DC, Davidson RE, and Mireles RJ, et al. (2007) Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-([2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino-methyl) -3-fluoro-phenoxy]-propionic acid in rat and human. Drug Metab Dispos 35:2111-2118.
11. Kalliokoski A and Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693-705.
12. Lau YY, Okochi H, Huang Y, and Benet LZ (2006) Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: Relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 34:1175-1181.
13. Nezasa K, Takao A, Kimura K, Takaichi M, Inazawa K, and Koike M (2002) Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor, in rat. Xenobiotica 32:715-727.
14. Paine SW, Parker AJ, Gardiner P, Webborn PJ, and Riley RJ (2008) Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab Dispos 36:1365-1374.
15. Shitara Y, Nagamatsu Y, Wada S, Sugiyama Y, and Horie T (2009) Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin a in rats. Drug Metab Dispos 37:1172-1178.
16. Soars MG, Grime K, Sproston JL, Webborn PJ, and Riley RJ (2007) Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos 35:859-865.
17. Takada Y, Tachizawa H, Kurihara H, Takayanagi M, Sasamoto T, Akashi M, Aiso M, Takamori Y, Sano N, and Takikawa H (2004) Comparison of urinary excretion of pravastatin and temocapril in bile duct-ligated rats and Eisai hyperbilirubinemic rats (EHBR). J Hepatobiliary Pancreat Surg 11:125-128.
18. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, and Fattinger K (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164-172.
19. Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, and Sugiyama Y (2010) Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos 38:215-222.
20. Ye ZW, Augustijns P, and Annaert P (2008) Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: Kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors. Drug Metab Dispos 36:1315-1321.
21. Zaher H, Meyer zu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, Palandra J, Stock JL, Kim RB, and Ware JA (2008) Targeted disruption of murine organic aniontransporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol 74:320-329.